Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient Travel Concerns After Treatment with 177Lu-DOTATATE.
Kendi AT, Mailman JA, Naraev BG, Mercer DJ, Underwood JK, Halfdanarson TR. Kendi AT, et al. Among authors: mailman ja. J Nucl Med. 2020 Apr;61(4):496-497. doi: 10.2967/jnumed.120.243238. Epub 2020 Mar 13. J Nucl Med. 2020. PMID: 32169915 Free article. No abstract available.
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.
Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR. Hope TA, et al. J Nucl Med. 2018 Jan;59(1):66-74. doi: 10.2967/jnumed.117.202275. Epub 2017 Oct 12. J Nucl Med. 2018. PMID: 29025982 Free PMC article. No abstract available.
NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy.
Hope TA, Bodei L, Chan JA, El-Haddad G, Fidelman N, Kunz PL, Mailman J, Menda Y, Metz DC, Mittra ES, Pryma DA, Reidy-Lagunes DL, Singh S, Strosberg JR. Hope TA, et al. Among authors: mailman j. J Nucl Med. 2020 Feb;61(2):222-227. doi: 10.2967/jnumed.119.240911. J Nucl Med. 2020. PMID: 32015164 Free PMC article. No abstract available.
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK. Del Rivero J, et al. Among authors: mailman j. J Clin Oncol. 2023 Nov 10;41(32):5049-5067. doi: 10.1200/JCO.23.01529. Epub 2023 Sep 29. J Clin Oncol. 2023. PMID: 37774329
Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.
Singh S, Ferone D, Capdevila J, Chan JA, de Herder WW, Halperin D, Mailman J, Hellström L, Liedman H, Svedberg A, Tiberg F. Singh S, et al. Among authors: mailman j. Trials. 2024 Jan 16;25(1):58. doi: 10.1186/s13063-023-07834-8. Trials. 2024. PMID: 38229199 Free PMC article. Clinical Trial.
20 results